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Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been
demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five
countries suggests that balancing the demands of research with clinical freedom has created structural
weaknesses that are being exploited.Although well-supported clinical applica-
tions of stem cells remain relatively few
in number (Daley, 2012), the use of
autologous adult stem cells (ASCs) in
advance of evidence from clinical trials
has become increasingly prevalent
(Bianco, 2013). Once mostly limited to
countries lacking the regulatory infra-
structure to monitor and control the
claims made by healthcare professionals
and institutions operating within their bor-
ders (Kiatpongsan and Sipp, 2008), these
practices have also emerged in places
such as the US, Australia, and Japan
(Lysaght et al., 2013). The global prolife-
ration of these practices raises serious
concerns about the exploitation of vulner-
able patient populations, the regulation of
novel cell-based therapeutics, and the
governance of medical professionals.
However, these practices appear less
prevalent in some countries with similar
standards in healthcare, scientific invest-
ment, and economic structure to the US,
Australia, and Japan—Singapore and
the UK are examples. The disparity sug-
gests that theremay be differences in reg-
ulatory systems that oversee clinical uses
of autologous ASCs in these countries
that may be encouraging or discouraging
their use outside the context of clinical
trials. To investigate this assertion, we
compared the regulatory regimes of the
US, Japan, Australia, Singapore, and the
UK (as a Member State of the European
Union) with the aim of identifying similar-
ities and differences in how autologous
ASCs are regulated and governed within
clinical contexts. We found that whilethere are many technical differences in
language and implementation, broad sim-
ilarities in the general regulatory approach
suggest that there is no one explanation
as to why these practices are more prev-
alent in some countries with apparently
well-developed regulatory frameworks.
Regulation of Stem Cells in
Research
All five countries examined have generally
supportive environments for basic scienti-
fic research using stem cells, with some
differences for lines derived from human
embryos (Ishii et al., 2013). More impor-
tantly, they have all adopted risk-based
approaches that regulate the use of
stem cells in clinical research as either
biological drug products or as medical
procedures. In all of these countries, cell
and tissue-based products (CTPs) that
are regulated as drugs and/or biologics
fall within the jurisdiction of a centralized
government agency that controls the
marketing of drugs, medical devices,
and biologics within each jurisdiction
(listed in Table 1 along with relevant laws
and regulations). Such products are con-
trolled through mandated premarket
testing for safety and efficacy in specified
indications, which usually involves a
sponsor obtaining an Investigational
New Drug (IND) designation and con-
ducting a series of registered multiphase
(I–III) clinical trials. Subsequent market
authorization may include additional re-
quirements for postmarket surveillance.
Yet, these requirements only apply to
products that are assessed as havingCell Stem Cell 13,higher than minimal risks, the definition
of which varies across jurisdictions.
Each country has exemptions that ex-
clude from regulation autologous cells
that have not been manipulated exten-
sively or combined with other articles,
are intended for homologous use in
functionally compatible tissues, and/or
are harvested and transplanted as part
of the same surgical procedure. For
example, hematopoietic stem cell trans-
plants using autologous grafts for the
reconstitution of bone marrow function
are not regulated as biological drugs in
any of these jurisdictions. Details about
the level of manipulation and intended
use of the cells vary across jurisdictions,
and the definitions used to described
these processes are often ambiguous
or undefined, but there is a general
consensus that these products do not
pose serious safety problems and are
thus subject to relatively limited regulatory
oversight. However, what constitutes
‘‘homologous use’’ is not clearly defined
in any of the regulations listed in Table 1,
and examples of processes that con-
stitute ‘‘nonsubstantial’’ or ‘‘minimal’’
manipulation, where stated, are not
exhaustive and differ from country to
country. Variations may therefore arise in
which cells are classified as ‘‘minimal
risk’’ and which are categorized as
requiring greater regulation in different
countries.
Even for highly manipulated products
that are regulated as drugs, clinical trial
sponsors and registered practitioners
may apply to special programs thatDecember 5, 2013 ª2013 Elsevier Inc. 647
Table 1. Agencies that Regulate Medicinal Drug Products
Jurisdiction Regulatory Agency Jurisdictional Laws and Regulations
United States Food and Drug Administration (FDA) Public Health Services Act (42 USC xx262, 264, 271); Code of Federal
Regulations (21 CFR x1271)
Japan Ministry of Health, Labour and
Welfare (MHLW)
Medical Practitioners Law, Law No. 201 of 1948; Practice Notice: Conducting
Regenerative and Cellular Medicine Using Autologous Cells and Tissues at
Medical Institutions (2010); Regenerative Medicine Law (draft)
Pharmaceuticals and Medical Device
Agency (PMDA)
Pharmaceutical Affairs Law, Law No. 145 of 1960, as amended
Australia Therapeutic Goods Administration (TGA) Therapeutic Goods Act (1989) and Regulations (1990) (Cth); Australian
Regulatory Guidelines for Biologicals
Singapore Ministry of Health (MOH) Private Hospitals and Medical Clinics Act (1980, revised 1999)
Health Sciences Authority (HSA) Medicines Act (1975, revised 1985); Medicines (Clinical Trials) Regulations
(1978, revised 2000); Health Products Act (2007)
United Kingdom Medicines and Healthcare Products
Regulatory Agency (MHRA)
The Medicines Act (1968); Human Medicines Regulations 2012 (SI 2012/1916)
European Medicines Agency (EMA) Advanced Therapy Medicinal Products Regulation (EC No 1394/2007)
and Directive (2001/83/EC)
Cell Stem Cell
Forumspeed the approvals process or provide
patients in exceptional circumstances
with access to medicinal products that
lack the evidence necessary for market
licensing. These programs differ in name
and some of the conditions vary across
jurisdictions. For example, so-called
‘‘compassionate use’’ or ‘‘special ac-
cess’’ provisions, such as the Expanded
Access Program in the US, provide
patients with access to experimental
agents that are the subject of an active
IND, and personal importation policies
such as the Named Patients Access
program in Japan allow, in exceptional
cases, importation for individual use
of drugs that have been approved in
an another country. In contrast, no
such restrictions apply for the Special
Access Scheme in Australia or the Spe-
cials Scheme and the Hospital Exemption
Scheme in the UK. Singapore does not
have a formal access program but, as
indicated below, registered practitioners
operating in licensed hospitals may, at
least in theory, offer unlicensed drugs to
patients under their care.
Regulation of Stem Cells in Clinical
Practice
The use of CTPs that are excluded
from regulation as drugs (i.e., minimally
manipulated autologous cells intended
for homologous use), along with regis-
tered products that are prescribed off-
license or off-label, are regulated as
medical practice, rather than medicinal
products. In all five countries, the practice648 Cell Stem Cell 13, December 5, 2013 ª2of medicine is not overseen by a central
regulatory agency, but is regulated sepa-
rately under complex frameworks of med-
ical licensing boards, health departments
and ministries, professional accreditation
bodies, third party payers, and negligence
laws (Taylor, 2010). Thus, while the laws
around advertising medicines vary in
each country, practitioners may lawfully
prescribe CTPs for indications that have
not received premarket approval within
the discretion of their professional judg-
ment. Where an intervention falls outside
the accepted standard of care, practi-
tioners generally need adequate justifica-
tion and may require special permission
from an institutions’ clinical practice or
governance board. If the intervention
is prescribed as part of a research pro-
tocol, then they may also need approval
from an institutional review board (IRB).
However, no permission or oversight is
required from the authorities that regulate
the marketing of the medicinal drugs in
any of these jurisdictions.
In addition, four of the five countries
have laws that explicitly allow the manu-
facture of CTPs under the supervision
of registered practitioners. In compliance
with Article 3(7) of the Advanced Therapy
Medicinal Products Directive (2001/83/
EC) of the EU, the UK excludes from
regulation any CTP that is ‘‘prepared on
a nonroutine basis’’ for use in a hospital
under ‘‘the exclusive responsibility of a
medical practitioner [.] for an individual
patient.’’ This ‘‘hospital use exemption’’
applies to other EU Member States, but013 Elsevier Inc.has been implemented differently accord-
ing to local interpretations of key terms,
such as ‘‘nonroutine,’’ leading to the
exemption being applied more liberally in
some countries (Mahalatchimy et al.,
2012). The European Commission is thus
currently considering the scope and
application of the directive (European
Commission, 2013).
The UK has also enabled the Specials
Scheme under the Medicines Act (1968)
and the Human Medicines Regulations
(2012), which provides exceptions for
medicinal products, including CTPs, that
are manufactured under the supervision
of a registered medical practitioner, or
by external vendors under a ‘‘specials’’
license that is obtained from the Medi-
cines and Healthcare Products Regu-
latory Agency. Singapore has similar
exemptions in the Medicines Act (1975,
revised 1985) for the preparation of
medicinal products by or under the
supervision of registered practitioners
operating within hospitals licensed under
the Private Hospitals and Medical Clinics
Act (1980, revised 1999). In Australia,
autologous cells that are manufactured
and administered by a registered practi-
tioner (or under their supervision) for a
patient under their care are excluded
from regulation under the Therapeutic
Goods Act (1989) in the Therapeutic
Goods (Excluded Goods) Order No. 1 of
2011.
In Japan, drugs that are administered
within the scope of a ‘‘physician’s discre-
tion’’ in medical practice fall under the
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not regulated by the Pharmaceuticals
andMedical Device Agency. Practitioners
using autologous ASCs need to observe
the Practice Notice: Conducting Regener-
ative and Cellular Medicine Using Autolo-
gous Cells and Tissue in Medical Institu-
tions (2010), but this only requires
approval from an internal review board.
A new law is currently being proposed
that will clarify the extent of freedom
licensed physicians have to prescribe un-
licensed CTPs within their ‘‘physician’s
discretion.’’ If enacted, medical institu-
tions that offer these products will be
required to register with the Ministry of
Health, Labour and Welfare. However,
following a risk-based approach, the law
will only require full ministerial approval
for pluripotent stem cells while IRB
approval will suffice for somatic stem-
cell-based products.
In these contexts, the manufacture of
CTPs must generally comply with current
Good Manufacturing Practices (or Good
Tissue Practice if not classified as drugs),
but their use is otherwise regulated
as clinical practice, not research. The
exception is the US, where the
manufacturing of biological drugs is
controlled solely by the Food and Drug
Administration (FDA), which has no
such exemptions for medical practi-
tioners to make and supply their own
drugs. However, the FDA’s jurisdiction
only applies to products, or ingredients
that make up those products, that are
shipped across state borders; the ques-
tion of whether this authority extends
to products made with ingredients
sourced and delivered entirely within
state borders, but which compete with
products sold in other states, remains
unresolved (Koustas and Fleder, 2011).
Regulation of these products presumably
falls under the jurisdiction of the medical
boards and health departments in each
American state.
Structural Weaknesses and the
Challenge for Regulators
Despite the many technical differences
in implementation and nomenclature,
the general approach in all five countries
is to provide a clear evidence-based
pathway for CTPs that are regulated as
medicinal drugs while allowing patients
to access low-risk interventions with
autologous ASCs under the supervisionof their physician. This approach is
designed to provide protections for
research subjects while maintaining
clinical autonomy for medical profes-
sionals and their patients. To support
these goals, all five jurisdictions have
implemented risk-based approaches to
the regulation of CTPs, giving regulators
a degree of flexibility in determining
the level of oversight and standards
of evidence that should apply before
these products are introduced onto the
market. However, as their use in clinical
practice is largely unregulated, the
approach also creates structural weak-
nesses that may be exploited by unscru-
pulous operators.
A key challenge that regulators face
in addressing these weaknesses is
ensuring that patients have the freedom
to access novel interventions while ac-
commodating the inherent uncertainties
of clinical research. While uncertainty is
a key characteristic of science—and
regulations, ethical guidelines, and gover-
nance processes can be designed
to minimize harms that may arise from
it—regulating clinical decisions in the
face of such uncertainty is often more
difficult. Across all five jurisdictions, regu-
lators and policymakers are generally
reluctant to interfere in decisions that
many would argue should remain within
the doctor-patient relationship. Yet, while
historically this has been politically and
culturally acceptable, few would agree
that physicians should be permitted carte
blanche authority in their practice of
medicine, unchecked by accountability
to their patients or to the social systems
that ultimately provide their healthcare.
Balancing professional and patient auto-
nomy with the need to provide therapies
that are evidence-based, yield ameaning-
ful benefit, and are affordable to the
community may, therefore, create a
potentially intractable problem for regu-
lators and policy-makers.
Regulators do have power to control
unethical and illicit clinical practices,
however, and a number of mechanisms
may be employed to control the use of
autologous ASCs outside clinical trials
without infringing on clinical freedoms or
stifling innovation in clinical care. Some
countries have already activated these
mechanisms by sanctioning offending
practitioners. In 2010, the British General
Medical Council deregistered Dr. RobertCell Stem Cell 13,Trossel for unjustifiably administering an
allogeneic cellular preparation (also found
to contain bovine neural cells) to patients
affected by multiple sclerosis at a clinic
in Rotterdam (General Medical Council,
2010). The Singapore Medical Council
has previously sanctioned four of its
practitioners for offering various stem
cell products without evidence of effi-
cacy, but has since withdrawn two
following an appeal (Low Chia Ling v
Singapore Medical Council, 2012;
Singapore Medical Council, 2009, 2010).
Florida’s Board of Medicine has also
revoked the license of Dr. Zannos Grekos
following the death of two patients after
or during procedures intended for the
delivery of autologous stem cell products,
a decision which is now under appeal
(Department of Health v Zannos Grekos,
2013). These enforcement actions may
not have deterred physicians from
routinely offering unproven interventions
with stem cells outside clinical trials, at
least not the US, although they are un-
likely to have harmed innovative practice
in any of these countries.
While these actions are commendable,
additional measures clearly need to be
taken over and above the sanctioning
and deregistration of individual practi-
tioners. For instance, better guidance
is needed to clarify the circumstances
in which autologous ASCs may be admin-
istered to patients before sufficient evi-
dence of safety and efficacy has been
established in clinical trials. The Texas
Medical Board (2012) has introduced
rules on the investigational use of human
stem cells that appear to provide an
alternative to the IND pathway by allowing
physicians to seek IRB approval to
prescribe agents not approved by the
FDA in their practice. These guidelines
have been the subject of extensive criti-
cism, principally because they appear
to substitute formal regulatory oversight
with IRB approval (Levine, 2012), even
though US federal manufacturing stan-
dards supersede state laws. The Practice
Notice in Japan also attempts to provide
guidance for physicians who use autolo-
gous cells in their practice by encouraging
ethics approval.
Where regulators can take greater
action is to enforce the existing laws
that regulate the advertising of medicinal
products. All five countries have tort
laws in place for medical negligenceDecember 5, 2013 ª2013 Elsevier Inc. 649
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restrict false advertising and the provision
of misleading information in medical
practice. Practitioners, healthcare pro-
viders, and manufacturers who create
websites and advertise the routine
use of interventions with autologous
ASCs that have not been established
as an accepted standard of care, or
provide misleading information about
the effectiveness of such interventions,
should be prosecuted under the relevant
laws. These laws can be activated without
infringing on the autonomy of patients
or practitioners who use innovative bio-
medicines responsibly and in the best
interests of those under their care.
No Single Solution
Given our comparative analysis of regu-
latory frameworks in the five countries
studied, it remains unclear why autolo-
gous ASCs are being prescribed outside
clinical trials more often in Australia,
Japan, and the US than in Singapore
and the UK. Although we found technical
differences in how key terms are defined
within the regulations, as well as
ambiguities that could be interpreted
differently across jurisdictions, these
do not sufficiently account for why
the use of autologous ASCs has pro-
liferated in some countries and not
others. All of these countries clearly
regulate clinical practice with an
emphasis on evidence-based medicine,
while allowing clinicians to develop
innovative care in a limited, responsible
manner and allowing patients to access
CTPs that lack the level of evidence
necessary for market authorization or
reimbursement from public and private
health insurers. While this approach may
support research and, in some cases,
work in the interests of patient autonomy
and access to care, it also creates
structural weaknesses that may be ex-
ploited by commercial interests who
either willfully misinterpret ambiguous
definitions in the regulation of drug
research or ignore them altogether.
In discouraging the exploitation of
vulnerable patient populations while
still ensuring scientific and clinical inno-
vation, relevant authorities should work
together in standardizing the terminology
and scientific processes used to define
and classify CTPs as minimal risk and
exclude them from regulation. The diffi-650 Cell Stem Cell 13, December 5, 2013 ª2culties seen in harmonizing regulations
across EU countries, however, suggest
that standardization across diverse juris-
dictions will be even more challenging,
as key terms may still be interpreted
and acted upon differently according
to national interests and the local needs
of patients. Scientific definitions and
evaluations of risk are also contestable.
Thus, the solution is unlikely to come
from simply clarifying and standardizing
nomenclature, although this could help
regulators improve the transparency of
drug designations.
In our opinion, the structural weak-
nesses described above manifest in the
separation of research regulation from
clinical governance, and solutions must
address how novel therapeutics are
introduced into the practice of medicine.
Safety alone is not sufficient to justify
routine clinical use of ASCs as even low
risk products should show compelling
evidence of efficacy before they are
introduced into healthcare systems and
accepted as the standard of care. While
we can activate and enforce existing
consumer protection laws and prohibi-
tions on false and misleading advertising
in medical practice, these are post hoc
mechanisms where the burden is placed
on adequately resourced patients and
authorities to demonstrate evidence of
wrongdoing, and in taking such action,
plaintiffs may potentially be exposed to
countersuits for libel. Medical authorities
also need to take a more proactive role
in sanctioning practitioners whose con-
duct falls outside accepted professional
standards and provide better guidance
for those who want to prescribe inno-
vative biomedicines responsibly before
evidence of efficacy has been established
in clinical trials. However, the impetus of
these actions remains with the medical
profession, and the lack of sanctions
against practitioners who continue
to prescribe autologous ASCs without
evidence of their efficacy suggests
that the self-regulatory model of clinical
governance is becoming outdated. New
models are needed to oversee the
introduction of novel CTPs into clinical
contexts in ways that acknowledge and
allow for scientific uncertainties while
enabling patient access to novel treat-
ments and ensuring that rigorous and
responsible research is unimpeded by
commercial interests.013 Elsevier Inc.ACKNOWLEDGMENTS
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